To evaluate the possible use of IGF2-P4 and H19 regulatory sequences for targeted therapy of bladder cancer, we determined the expression of IGF2-P4 and H19 transcripts by RT-PCR, qRT-PCR and ISH. The gene discussed is IGF2; the disease is urinary bladder carcinoma.